結腸直腸がんにおける分子プロファイリング指向の個別化補助療法:臨床格差に対するコンセンサスのガイドラインを橋渡しする
1Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China. xfcheng@zju.edu.cn.
World journal of gastroenterology
|February 16, 2026
まとめ
分子プロフィーリングは,大腸直腸がん (CRC) の補助療法を,従来のステージングを超えて変革しています. 鍵となるバイオマーカーはリスクと治療を洗練しますが,実装のギャップが依然として存在し,パーソナライズされたケアのための統合的なソリューションが必要です.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 精密医療とは
背景:
- 結腸直腸がん (CRC) の補助療法では,ステージベースのアプローチから分子プロファイリングによるアプローチに移行しています.
- 鍵となるバイオマーカーは,CRCにおけるリスクの階層化と治療の選択を精密にするために極めて重要です.
研究 の 目的:
- CRC補助療法におけるバイオマーカーの進化する役割を検討する.
- 実施のギャップを特定し,パーソナライズされたCRC処理のための解決策を提案します.
主な方法:
- CRCバイオマーカーと補助療法 (2010-2025) のための包括的な文献検索 (PubMed, Web of Science).
- 重要なバイオマーカーの分析:不一致修復 (MMR) ステータス,RAS変異,コンセンサス分子サブタイプ,および循環腫瘍DNA (ctDNA).
主要な成果:
- MMRステータスやctDNAのようなバイオマーカーは,CRCにおけるリスクの分層化と治療選択を洗練します.
- 現実世界の実施における格差は,テストの変動性,証拠の進化,経済的な障壁により持続しています.
結論:
- 実施のギャップを解決するには,技術革新 (AI,マルチオミクス,ctDNAモニタリング),最適化された臨床経路,支援政策が必要です.
- 分子洞察をCRC患者の公平で個別化された補助ケアに変換するために,多学科の協力が不可欠です.
関連する概念動画
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
15
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenomics: Identification of New Drug Targets
9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9


